News | Cath Lab | May 15, 2018

Culprit Vessel Only Strategy Has Lower Mortality Than Routine Multivessel Intervention

New study compares two different PCI strategies for patients with acute myocardial infarction and cardiogenic shock

Angiogram of a STEMI patient.

May 15, 2018 — A contemporary, real-world analysis shows lower mortality rates when culprit-only intervention is used for patients with multivessel disease (MVD) and acute myocardial infarction (AMI) with cardiogenic shock (CS). In a new study, percutaneous coronary intervention (PCI) of the culprit vessel was associated with improved outcomes, despite the majority of these patients having multivessel disease (MVD). The data was presented as late-breaking clinical science at the 2018 Society for Cardiovascular Angiography and Interventions (SCAI) Scientific Sessions.[1]

Whether or not PCI of non-culprit disease in the acute setting improves outcomes is unclear. The results of this new study come on the heels of the recent randomized CULPRIT-SHOCK trial[1] that was the first to find revascularization of all significant non-culprit lesions worsens outcomes. The late-breaking clinical science study is the most recent study to compare the two PCI strategies in this patient population.

The study assessed culprit vessel intervention (CVI) versus MVI in 649 patients with AMI, CS and MVD that were enrolled in the British Columbia Cardiac Registry (2008-2014). All-cause mortality was evaluated at 30 days and one-year.

Compared with MVI, CVI was associated with lower mortality at 30 days (23.7 vs. 34.5 percent) and one-year (32.6 vs. 44.3 percent). CVI was an independent predictor for survival at 30 days (HR=0.78, 95 percent Cl: 0.64-0.97, p=0.023) and one-year (HR=0.78, 95 percent Cl: 0.64-0.97, p=0.023). The findings were confirmed in propensity-matched cohorts. Overall, in patients with AMI and CS, a CVI approach was associated with lower mortality.

“The comparison between culprit-only and multivessel intervention is a hot topic of conversation and debate in our field, and the results of our study add to the recent CULPRIT-SHOCK trial and help us better understand the positive outcomes of a culprit-only approach,” said lead author Bilal Iqbal, M.D., Victoria Heart Institute Foundation, Canada. “The CULPRIT-SHOCK trial is the largest body of randomized evidence in the CS population. The recent Korean registry has shown that MVI may be better, but there are differences in the definition of MVI, making comparison difficult. Importantly, in CULPRIT-SHOCK and our study, MVI was defined as non-culprit PCI at the time of index intervention, and CVI was defined as PCI of culprit vessel only at the time of index intervention. Whereas in the Korean registry, MVI included non-culprit PCI, even if it were performed as an in-hospital staged procedure. Thus, it is conceivable that by adopting the definition of CVI used in our study and CULPRIT-SHOCK, the Korean study may have yielded different results.”

The authors call for more randomized studies to further evaluate the two PCI strategies for this patient population in order to gain a better understanding of the safety and feasibility of culprit-only lesion approach.

Complete listing of SCAI 2018 late-breaking trials with links to articles.

 

References: 

1. McNeice A, Nadra I, Robinson SD. et al. The prognostic impact of revascularization strategy in acute myocardial infarction and cardiogenic shock: Insights from the British Columbia Cardiac Registry. Catheter Cardiovasc Interv. 2018 Apr 26. doi: 10.1002/ccd.27648. [Epub ahead of print]

2. Holger Thiele, Ibrahim Akin, Marcus Sandri, et al. PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock. N Engl J Med 2017; 377:2419-2432. DOI: 10.1056/NEJMoa1710261

 

Related Content

News | Cardiovascular Clinical Studies

June 24, 2021 — Data captured in American College of Cardiology (ACC) National Cardiovascular Data Registry (NCDR) ...

Home June 24, 2021
Home
News | Cardiovascular Clinical Studies

January 27, 2021 — A New York Institute of Technology research team has secured a five-year $1.8 million grant from the ...

Home January 27, 2021
Home
News | Cardiovascular Clinical Studies

July 22, 2020 — Eating chocolate at least once a week is linked with a reduced risk of heart disease, according to ...

Home July 22, 2020
Home
News | Cardiovascular Clinical Studies

July 1, 2020 — Carag AG announced receiving U.S. Food and Drug Administration (FDA) Investigational Device Exemption ...

Home July 01, 2020
Home
News | Cardiovascular Clinical Studies

January 20, 2020 — Scientists at Los Alamos and international partners have created the first 3-D images of a special ...

Home January 20, 2020
Home
News | Cardiovascular Clinical Studies

Environmental and lifestyle issues were popular this year, with pick up from both European Society of Cardiology (ESC) ...

Home December 23, 2019
Home
News | Cardiovascular Clinical Studies

November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have ...

Home November 26, 2019
Home
News | Cardiovascular Clinical Studies

July 10, 2019 — The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During ...

Home July 10, 2019
Home
News | Cardiovascular Clinical Studies

July 3, 2019 — The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to ...

Home July 03, 2019
Home
News | Cardiovascular Clinical Studies

November 19, 2018 — The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent ...

Home November 19, 2018
Home
Subscribe Now